Discover more near‑term opportunities with better event intelligence.

Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce

4.8/5 on G2· Since 2015

Oxurion to acquire Eclevar's assets in France

PRIVATESep 30, 2026

Acquiring Company

Oxurion

Acquired Company

Eclevar

Boston

FranceSoftwareConsumer GoodsBiotechnologyHealth CareMedical

Description

Oxurion has entered into exclusive negotiations to acquire Eclevar, a French CRO specializing in medical devices. The transaction is based on a pricing mechanism linked to Eclevar's future profitability and is targeted for completion by the end of 2026. This acquisition aims to enhance Oxurion's capabilities in the MedTech sector.

Company Information

Company

Oxurion

Location

Boston, Massachusetts, United States

About

Taken together with cash on hand, the Debt Financing is not sufficient to execute the Company’s current business plan for the next 12 months without the Company accessing the further EUR 22.5 million available from the Negma Group during that period under the funding program in place, which is subject to certain conditions. Momi Karako, Partner of Pontifax Ventures, commented “Oxurion is developing a truly innovative pipeline of novel assets, which are uniquely positioned to disrupt and grow the more than $12 billion anti-VEGF market. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and retinal vein occlusion (RVO).

Fundz sees it the moment Oxurion makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Predictive Intelligence

Strategic

ML-powered predictions for Oxurion's next move

Learn about Strategic plan

Frequently asked

Who acquired Eclevar?

Eclevar was acquired by Oxurion, based in Boston. The deal was reported on September 30, 2026. Oxurion is privately held and operates in Software.

When did Oxurion acquire Eclevar?

Oxurion's acquisition of Eclevar was reported on September 30, 2026. Oxurion has entered into exclusive negotiations to acquire Eclevar, a French CRO specializing in medical devices. The transaction is based on a pricing mechanism linked to Eclevar's future profitability and is targeted for completion by the end of 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Eclevar do?

Eclevar is a French clinical research organization (CRO) specializing in the medical devices industry. Over the past years, it has developed a significant customer base across Europe, Japan, and China. It is privately held, operating in Biotechnology, and is based in France.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Show me how a services firm uses this Or see plans and pricing →

5 screens from a live account. No signup.